Welcome to our dedicated page for Dare Bioscience news (Ticker: DARE), a resource for investors and traders seeking the latest updates and insights on Dare Bioscience stock.
News about Daré Bioscience, Inc. (NASDAQ: DARE) centers on its efforts to advance and commercialize women’s health products across contraception, sexual health, vaginal health and menopause. Company press releases highlight progress on clinical programs, grant-funded research, regulatory interactions and commercialization plans for both prescription and consumer health offerings.
Recent news has focused on DARE to PLAY Sildenafil Cream, a proprietary topical arousal cream designed specifically for women. Daré reports that this first-of-its-kind topical sildenafil formulation for women has been evaluated in multiple clinical studies and is being introduced via a Section 503B outsourcing facility as an evidence-backed option to enhance genital blood flow and arousal response. Updates describe pre-order availability in select U.S. states, webinar events with sexual health clinicians and the role of DARE to PLAY in the company’s broader 503B compounding strategy.
Another major news theme is Ovaprene, Daré’s investigational hormone-free monthly intravaginal contraceptive. Releases discuss interim Phase 3 results, data safety monitoring board recommendations to continue the pivotal study without modification, and the return of commercialization rights to Daré from a prior license partner. These items provide context on clinical progress, safety and tolerability findings, and the company’s plans to maximize the asset’s value.
Daré’s news flow also covers non-dilutive grant funding and collaborations, including multi-year support for DARE-LARC1, a long-acting contraceptive based on the DARE-IDDS programmable drug delivery platform, and grants for non-hormonal intravaginal contraceptive research and HPV-related programs. Corporate updates detail quarterly financial results, Nasdaq listing matters, and strategic initiatives that combine near-term revenue opportunities with long-term pipeline development. Investors and observers can use the DARE news page to follow these developments and track how clinical, commercial and funding milestones evolve over time.
Daré Bioscience, a leader in women’s health innovation, announced its President and CEO, Sabrina Martucci Johnson, will present at two major conferences: the 2022 BIO CEO & Investor Conference (February 14-17, 2022) and the SVB Leerink Virtual 11th Annual Global Healthcare Conference (February 14-18, 2022). Johnson's in-person presentation at the BIO CEO Conference is scheduled for February 14 at 2:15 p.m. EST, while her SVB Leerink presentation will be on February 17 at 1:00 p.m. EST. Archived webcasts will be available post-event on Daré's website.
Daré Bioscience (NASDAQ: DARE) announced that President and CEO Sabrina Martucci Johnson will present at the H.C. Wainwright BIOCONNECT 2022 Conference, taking place virtually from January 10-13, 2022. Her presentation will be available on-demand starting January 10 at 7:00 a.m. ET, and accessible under the Investors section of the company’s website. A recorded version will be available until January 27, 2022. Daré focuses on innovative women’s health products, including their FDA-approved product XACIATO and various clinical candidates.
On December 7, 2021, Daré Bioscience announced FDA approval for XACIATO (clindamycin phosphate vaginal gel, 2%), marking a significant milestone as it becomes the company's first FDA-approved product targeting bacterial vaginosis in women aged 12 and older. With over 21 million women affected, XACIATO aims to address the high recurrence rate of bacterial vaginosis and improve treatment outcomes. The company is pursuing strategic partnerships for commercialization, with expectations for a U.S. launch in 2022.
Daré Bioscience (NASDAQ: DARE) reported significant progress in Q3 2021, with the FDA accepting the NDA for DARE-BV1, targeting a PDUFA action date of December 7, 2021. The company entered a CRADA for Ovaprene's pivotal Phase 3 study and initiated a Phase 1/2 study for DARE-VVA1. Financially, Daré had cash equivalents of $45.6 million and a comprehensive loss of $12.7 million. R&D expenses rose to $10.4 million, driven by clinical trials. The company anticipates robust market introduction for DARE-BV1 in H1 2022, pending FDA approval.
Daré Bioscience (NASDAQ: DARE) announced that CEO Sabrina Martucci Johnson will present at the Stifel 2021 Virtual Healthcare Conference on November 16, 2021, at 3:20 p.m. ET. A live webcast of the presentation will be available, with an archived version accessible until November 30, 2021. Daré focuses on innovative products for women's health, with a portfolio including potential first-in-category therapies like Ovaprene® and Sildenafil Cream, 3.6%. The company aims to enhance treatment options in contraception, fertility, and sexual health.
Daré Bioscience (NASDAQ: DARE) will host a conference call on November 10, 2021, at 4:30 p.m. ET to discuss its financial results for Q3 2021 and provide an update on the company. Interested parties can join via phone or through a live webcast available on their website. Daré is focused on women's health, with products in development including Ovaprene, Sildenafil Cream, DARE-BV1, and DARE-HRT1, aimed at contraception, sexual health, and hormone therapy.
Daré Bioscience (NASDAQ: DARE) announced participation in the Xpectives.Health Summit in Boston, MA, from October 12-14, 2021. Sabrina Martucci Johnson, the company’s President and CEO, will join an expert panel to discuss the pharmaceutical industry's commitment to advancing women’s health innovation. The panel, titled Industry and Investors Commitment to Women’s Health, is scheduled for October 14, 2021, from 2:00 to 2:45 pm ET. Daré focuses on developing products that address unmet needs in areas such as contraception, vaginal health, and fertility.
Daré Bioscience announced a Notice of Award from the NICHD granting $309,614 to support the development of DARE-LARC1, a user-controlled long-acting reversible contraceptive (LARC). This funding adds to a previously announced grant of up to $48.95 million. DARE-LARC1 is designed for self-administration, offering flexibility for women to pause or resume contraception without medical intervention. The project aims to meet the unmet needs in women's health while ensuring a comparable contraceptive effectiveness to existing LARCs.
Daré Bioscience has initiated a Phase 1/2 clinical study of DARE-VVA1, an investigational intravaginal tamoxifen product aimed at treating moderate to severe vulvar and vaginal atrophy (VVA) in postmenopausal women, particularly those with hormone receptor-positive breast cancer. The study will assess the safety, pharmacokinetics, and pharmacodynamics of four different doses of DARE-VVA1 over a treatment period of 56 days. This offers a potential non-hormonal alternative to estrogen-based therapies, addressing unmet needs in women's health.
Daré Bioscience (NASDAQ: DARE) will feature its President and CEO, Sabrina Martucci Johnson, at the Virtual Global Healthcare Conference from September 27 to 30, 2021. Johnson's presentation is scheduled for September 30 at 12:40 p.m. ET. Investors can access a live webcast at this link, with an archived version available until October 15, 2021, on the company's investor website. Daré is known for its commitment to advancing innovative women’s health products, including Ovaprene® and Sildenafil Cream, 3.6%.